Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun;13(6):4933-4938.
doi: 10.3892/ol.2017.6095. Epub 2017 Apr 25.

Differences in the sensitivity of ovarian cancer to photodynamic therapy and the mechanisms for those differences

Affiliations

Differences in the sensitivity of ovarian cancer to photodynamic therapy and the mechanisms for those differences

Yoshihito Yokoyama et al. Oncol Lett. 2017 Jun.

Abstract

Protoporphyrin IX (PpIX) levels are crucial to the antitumor action of photodynamic therapy (PDT). In the present study, the underling molecular mechanisms for the variation in PpIX levels in ovarian cancer cells were investigated. Five ovarian cancer cell lines were subcutaneously grafted onto the backs of nude mice. Once tumors had developed, 5-aminolevulinic acid methyl ester hydrochloride (methyl-ALA) was administered intraperitoneally and the tumor was irradiated twice/week. PpIX levels in the tumor were assayed using high-performance liquid chromatography. Enzymes involved in heme synthesis and degradation were screened using a microarray technique. Expression of the glutathione transferase Omega-1 (GSTO1) gene involved in the conversion of PpIX into heme in cells was quantified using the reverse transcription-quantitative polymerase chain reaction. In HTOA, HRA and DISS cells, PDT resulted in significant tumor shrinkage in comparison with the controls. In MCAS and TOV21G cells, no significant alterations in tumor growth were identified compared with the untreated cells. PpIX levels increased significantly in HTOA, DISS and HRA cells compared with in MCAS and TOV21G cells. A comparison of genetic profiles using PDT-sensitive DISS cells and PDT-resistant MCAS cells indicated that MCAS cells exhibited significantly increased levels of δ-aminolevulinate synthase (a rate-limiting enzyme in heme synthesis), heme oxygenase 2 (an enzyme that degrades heme into biliverdin), and biliverdin reductase B (an enzyme that reduces biliverdin into bilirubin) in comparison with DISS cells. The level of GSTO1 expression in HTOA, HRA and DISS cells was ~2.5-fold that in MCAS and TOV21G cells. Sensitivity to PDT is related to PpIX levels in cells. The results of the present study suggested that PpIX tends not to accumulate in PDT-resistant cells despite active heme synthesis and degradation, and that high levels of GSTO1 expression are associated with increased sensitivity to PDT.

Keywords: 5-aminolevulinic acid methyl ester hydrochloride; glutathione transferase Omega-1; ovarian cancer; photodynamic therapy; protoporphyrin IX.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Antitumor effect of methyl-ALA-PDT on tumor derived from five ovarian cancer cell lines. In HTOA, HRA and DISS tumor cells, PDT resulted in significant tumor shrinkage in comparison with the untreated control cells. In MCAS and TOV21G cells, no significant differences in tumor growth were identified between the PDT group and the control cells.
Figure 2.
Figure 2.
Schematic diagram of the heme synthetic and degradation pathways.
Figure 3.
Figure 3.
Determination of the GSTO1 gene in ovarian cancer cells. The expression level of GSTO1 in HTOA, HRA and DISS cells was between 2 and 2.5-fold that in MCAS and TOV21G cells. P<0.001 vs. MCAS cells; §P<0.001 vs. TOV21G. GSTO1, glutathione transferase Omega-1; Actb, β-actin.

Similar articles

Cited by

References

    1. Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, van Gorp T, Trillsch F, Mahner S, Ulmer H, et al. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma-analysis of patient data in the prospective OVCAD study. Gynecol Oncol. 2013;131:15–20. doi: 10.1016/j.ygyno.2013.07.086. - DOI - PubMed
    1. Akeson M, Zetterqvist BM, Dahllöf K, Brännström M, Horvath G. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: A population-based cohort study of all patients in western Sweden with long-term follow-up. Acta Obstet Gynecol Scand. 2008;87:1343–1352. doi: 10.1080/00016340802495491. - DOI - PubMed
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. doi: 10.3322/caac.21166. - DOI - PubMed
    1. Casson AG. Photofrin PDT for early stage esophageal cancer: A new standard of care? Photodiagnosis Photodyn Ther. 2009;6:155–156. doi: 10.1016/j.pdpdt.2009.09.002. - DOI - PubMed
    1. Ikeda N, Usuda J, Kato H, Ishizumi T, Ichinose S, Otani K, Honda H, Furukawa K, Okunaka T, Tsutsui H. New aspects of photodynamic therapy for central type early stage lung cancer. Lasers Surg Med. 2011;43:749–754. doi: 10.1002/lsm.21091. - DOI - PubMed